Vol

When Volume Matters, Immunoassay Systems Deliver

Although new and innovative technology has enabled more and more laboratory testing to occur at the bedside or physicians office, the central laboratory is hardly threatened with extinction. National volume data suggest that medium and large labs are busier than ever before, and the huge range of their capabilities, gold standard reliability and ability to handle very large volumes of tests a...

Appendicitis: Evolving Tools to Diagnose a Classic Disease

Contributing Editor Appendicitis is a common, potentially lethal condition that affects 7% of individuals sometime in their lives. The condition occurs when the appendix, a blind pouch of intestine at the proximal colon, becomes obstructed by mucus, stool, or lymphatic tissue. Infection ensues, which can rapidly evol...

Mild Asthma, a Revolutionary Therapy from Italian Research

Published by the New England Journal of Medicine the B.E.S.Tstudy conducted in Italy “TAKEN ONLY WHEN NEEDED AND THE DISEASE CAN BE CONTROLLEDSUCCESSFULLY” Prof. Fabbri: “Daily drug useless for mild persistenttypes affecting over one million 200 thousand people”.Chiesi’s commitment to pneumological research MILAN, Italy, 29th May 2007 &nda...

Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure as Long-Term Monotherapy and in Combination Therapy

Data Also Show Nebivolol Lowers Blood Pressure in Obese andNon-Obese Hypertensive Patients CHICAGO, May 21, 2007 /PRNewswire-FirstCall/ -- ForestLaboratories, Inc. today presented positive data from two clinicalstudies and one pooled analysis of nebivolol, a selective beta1-blocker with vasodilating properties currently under review bythe U.S. Food and Drug Administration (FDA) for the tr...

Revolutionary Immunologic Data Explains Function of Diamyd Diabetes Vaccine

Diamyd Medical AB (<a target="_blank" href="http://www.omxgroup.com/">www.omxgroup.com ticker: DIAM B; ticker DMYDY) STOCKHOLM, Sweden, May 3, 2007 – During a presentationmade in Linkoping, Sweden at the Sweden-Seattle Diabetes Conferencethis past week-end, Professor Johnny Ludvigsson, the Principal...

CSL Therapy That Mimics “Good” Cholesterol May Reduce Plaque Volume in Coronary Arteries

VICTORIA, Australia, March 27, 2007--CSL Limitedtoday announced results from a study published in the Journal ofthe American Medical Association that suggest infusions of a novelnew drug, CSL-111, to acutely raise HDL (“good”cholesterol) levels, may reduce the amount of plaque in thecoronary arteries of patients with a recent episode of acutecoronary syndrome (AC...

CSL Therapy That Mimics 'Good' Cholesterol May Reduce Plaque Volume in Coronary Arteries

NEW ORLEANS, March 26, 2007 /PRNewswire/ -- CSL Limited todayannounced results from a study published in the Journal of theAmerican Medical Association that suggest infusions of a novel newdrug, CSL-111, to acutely raise HDL ("good" cholesterol) levels,may reduce the amount of plaque in the coronary arteries ofpatients with a recent episode of acute coronary syndrome(ACS). ACS is...